Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVGN6051 Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Malignancy
NCT04130542Phase 1Completed
- Sponsor
- Lijin Biomedical Technology
- Start
- Oct 2019
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exlinkibart in cancer, sponsored by Lijin Biomedical Technology. Primary endpoint: Safety and Tolerability up to 24 months. Started Oct 2019; status: completed.
02
Drugs
exlinkibart
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04130542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130542.